FIA
RNA

FNY Investment Advisers’s Atrium Therapeutics RNA Stock Holding History

FNY Investment Advisers’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-78
Closed -$1K – 1133
2026
Q1 		$1K Buy
+78
New +$1.1K ﹤0.01% 743

Other funds holding RNA

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FI
Fractal Investments Glastonbury, Connecticut $867M AUM 23.63% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

FNY Investment Advisers's RNA Position: Q2 2026 in Review

FNY Investment Advisers opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 260 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #739 among its holdings.

27 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • FNY Investment Advisers held 260 shares of Atrium Therapeutics worth $3K as of Q2 2026.
  • Atrium Therapeutics was a new FNY Investment Advisers position in Q2 2026.
  • Atrium Therapeutics made up ﹤0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #739 holding.
  • 27 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.